A landmark moment in global public health is unfolding as the European Medicines Agency (EMA) and the African Medicines Agency (AMA) have joined forces to tackle the burgeoning Ebola virus disease outbreak caused by the Bundibugyo virus in the Democratic Republic of the Congo (DRC) and Uganda. This signifies the first time these two regulatory bodies have collaborated on a public health emergency since the AMA’s inception in 2021, marking a crucial step forward in coordinated international response to infectious disease threats.
The urgency of this collaboration stems from the World Health Organization’s (WHO) declaration on May 17th, designating the outbreak as a Public Health Emergency of International Concern (PHEIC). This critical designation highlights the significant risk posed by the disease and the need for a robust, multi-faceted response.
The Threat of Bundibugyo Virus: A New Frontier in Ebola Response
While Ebola virus disease is a grim reality, the current outbreak presents a unique challenge. Unlike the more frequently encountered Zaire ebolavirus, for which approved vaccines and treatments exist, the Bundibugyo virus has historically lacked specific, authorized medical countermeasures. This void necessitates a rapid and targeted approach to research, development, and deployment of effective interventions.
The EMA’s Emergency Task Force (ETF) has been proactively exploring potential vaccine and treatment candidates for the Bundibugyo virus. Their diligent work has identified several promising avenues for further investigation and clinical development. These include:
-
Vaccine Candidates:
- A recombinant vesicular stomatitis virus (rVSV)-based vaccine targeting the Bundibugyo virus.
- A vaccine utilizing the ChAdOx1 modified adenovirus platform, specifically engineered for the Bundibugyo virus.
- An mRNA vaccine, a rapidly advancing technology that has demonstrated success in other infectious disease contexts.
-
Treatment Candidates:
- Mapp Biopharmaceutical’s MBP-134, a combination of two monoclonal antibodies (mAbs) demonstrating activity against various ebolaviruses, including Bundibugyo virus.
- Gilead’s established antiviral Veklury (remdesivir), which may offer a broad spectrum of activity.
- Regeneron’s mAb Inmazeb (maftivimab), another promising monoclonal antibody therapeutic.
-
Post-Exposure Prophylaxis:
- Gilead’s antiviral obeldesivir has been identified as a potential medicine for post-exposure prophylaxis, offering a critical tool to prevent infection after potential exposure.
The development of these potential interventions is particularly significant given the limitations of existing countermeasures designed for the Zaire ebolavirus. Vaccines like MSD’s Ervebo, and the two-dose regimen of Johnson & Johnson’s Zabdeno and Mvabea, are primarily effective against Zaire. Consequently, bespoke solutions are imperative for the current Bundibugyo outbreak. While some investigational pan-filovirus mAbs and other antivirals are in development and may exhibit some efficacy against Bundibugyo, their effectiveness requires rigorous clinical validation.
A New Era of Regulatory Collaboration: EMA and AMA Unite
The formation of the EMA and AMA collaboration is a pivotal development, underscoring a commitment to a more integrated and responsive global health security framework. The EMA’s ETF, with its expertise in evaluating and authorizing medicines, is now working hand-in-hand with the AMA, an organization dedicated to harmonizing and strengthening regulatory systems across Africa.
This joint effort is further bolstered by the invaluable input from the WHO-AFRO African Vaccines Regulatory Forum (AVAREF). AVAREF plays a crucial role in advising on vaccine research and development for diseases prevalent in Africa, bringing essential regional expertise and perspectives to the table.
Designing the Future of Clinical Trials: A Comprehensive Approach
The immediate focus of this unprecedented partnership is the meticulous design of clinical trials for the identified vaccine and treatment candidates. The discussions are set to encompass a broad spectrum of therapeutic applications, ensuring that the trials are comprehensive and address the diverse needs presented by the Bundibugyo virus outbreak. Key areas of focus for clinical trial design include:
- Prophylaxis: This includes both preventative vaccination strategies and post-exposure prophylaxis (PEP) to prevent infection in individuals who may have been exposed to the virus. The aim is to determine the efficacy and safety of interventions in preventing disease onset.
- Treatment of Bundibugyo Virus Disease: Trials will rigorously evaluate the effectiveness of candidate treatments in managing active infections, aiming to reduce mortality, morbidity, and transmission.
- All Age Groups: A critical aspect of the trial design will be to ensure inclusivity across all age demographics, from infants to the elderly. This acknowledges that the impact and response to the virus can vary significantly across different age groups, and interventions must be safe and effective for everyone.
The collaborative effort aims to move these promising candidates through the entire clinical development pathway, from early-phase studies to large-scale pivotal trials that will inform regulatory decisions and ultimately, the deployment of life-saving interventions.
Chronology of a Public Health Emergency and Collaborative Response
The current situation has unfolded rapidly, necessitating swift and decisive action:
- Recent Months: The EMA’s Emergency Task Force (ETF) has been actively engaged in identifying and evaluating potential vaccine and treatment candidates for the Bundibugyo virus, recognizing the growing threat posed by emerging viral strains.
- May 17th: The World Health Organization (WHO) officially declared the Ebola virus disease outbreak, caused by the Bundibugyo virus, in the Democratic Republic of the Congo and Uganda as a Public Health Emergency of International Concern (PHEIC). This declaration signals a significant and sustained risk to international public health and necessitates a coordinated global response.
- Following the PHEIC Declaration: The EMA’s ETF initiated engagement with the African Medicines Agency (AMA) to strategize and plan clinical trials for the identified candidates. This marked the formal commencement of their historic collaboration.
- Ongoing: The EMA and AMA, in conjunction with the WHO-AFRO African Vaccines Regulatory Forum (AVAREF), are actively engaged in detailed discussions regarding the design of clinical trials. This process is crucial for ensuring the scientific rigor and ethical conduct of future studies.
Supporting Data and the Scientific Rationale
The identification of these specific vaccine and treatment candidates is not arbitrary. It is based on a combination of scientific understanding of Ebola viruses, advancements in medical technology, and the observed characteristics of the Bundibugyo strain.
- rVSV-based Vaccines: The rVSV platform has proven successful in developing effective vaccines for other viral hemorrhagic fevers, including the rVSV-ZEBOV vaccine (Ervebo) against the Zaire ebolavirus. This existing success provides a strong scientific basis for exploring its application against Bundibugyo.
- ChAdOx1 Platform: The chimpanzee adenovirus vector (ChAdOx1) platform has been utilized in the development of vaccines for other diseases, demonstrating its capacity to elicit robust immune responses. Adapting this platform for Bundibugyo virus offers another promising avenue.
- mRNA Technology: The rapid development and deployment of mRNA vaccines against COVID-19 have revolutionized vaccine development. This technology’s ability to quickly generate vaccines against novel pathogens makes it a highly attractive option for emerging threats like the Bundibugyo virus.
- Monoclonal Antibodies (mAbs): Monoclonal antibodies are highly specific proteins that can neutralize viruses by binding to critical viral components. The success of mAbs like Inmazeb against Zaire ebolavirus suggests their potential efficacy against Bundibugyo, especially if they target conserved regions of the virus or different ebolavirus species.
- Antivirals: Antiviral drugs work by inhibiting viral replication. Established antivirals like remdesivir, and novel ones like obeldesivir, have demonstrated activity against various viruses, making them candidates for treating Bundibugyo virus disease and for post-exposure prophylaxis.
The scientific rationale for customising interventions is clear. The genetic and antigenic differences between Bundibugyo virus and Zaire ebolavirus mean that existing countermeasures may not be sufficiently effective. Therefore, the current collaborative efforts are focused on developing tailored solutions that directly address the specific characteristics of the Bundibugyo strain.
Official Responses and the Significance of AMA’s Role
The establishment of the African Medicines Agency (AMA) in 2021 was a pivotal moment for public health on the continent. Its mandate to harmonize medicinal product regulation across African Union member states is designed to accelerate access to safe, effective, and quality-assured medicines and vaccines. This current collaboration with the EMA exemplifies the AMA’s growing influence and capability in addressing critical health emergencies.
Dr. John Nkengasong, Director of the Africa Centres for Disease Control and Prevention (Africa CDC) and a key proponent of the AMA, has consistently emphasized the need for African leadership in health security. This joint initiative with the EMA allows the AMA to leverage its regional expertise and regulatory framework to directly contribute to the development and deployment of interventions for an outbreak on its doorstep.
The EMA, as a globally recognized regulatory authority, brings its extensive experience in drug evaluation and approval processes. By sharing this expertise and working collaboratively with the AMA, the partnership aims to ensure that any approved interventions meet the highest international standards while also being accessible and relevant to the African context.
Implications for Global Health Security
This unprecedented collaboration between the EMA and AMA has far-reaching implications for global health security:
- Enhanced Preparedness and Response: The joint effort demonstrates a proactive approach to emerging infectious disease threats. By working together from the outset of an outbreak, regulatory agencies can significantly accelerate the availability of life-saving interventions.
- Strengthened African Regulatory Capacity: This collaboration provides a valuable opportunity for the AMA to further develop its expertise and operational capacity in managing public health emergencies. This will have long-term benefits for the continent’s ability to respond to future health crises.
- Harmonized Regulatory Pathways: The partnership can foster greater alignment in regulatory approaches between Europe and Africa, potentially streamlining future drug development and approval processes for diseases that affect both regions.
- Equitable Access to Medicines: By ensuring that interventions are developed with the needs of affected populations in mind, this collaboration increases the likelihood of equitable access to essential medicines and vaccines, a critical component of global health justice.
- Model for Future Collaborations: The success of this EMA-AMA partnership could serve as a powerful model for future collaborations between regional and international regulatory bodies, fostering a more cohesive and effective global response to pandemics and other health emergencies.
The ongoing Ebola outbreak caused by the Bundibugyo virus in the DRC and Uganda is a stark reminder of the persistent threat posed by infectious diseases. However, the historic collaboration between the European Medicines Agency and the African Medicines Agency offers a beacon of hope. By pooling their expertise and resources, these agencies are setting a new standard for international cooperation, demonstrating a unified commitment to protecting global health and saving lives in the face of adversity. The coming months will be critical as they work to translate identified candidates into tangible solutions for those most in need.
About the Author
